Connect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, MarketBeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Other analysts have also issued research reports about the stock. Piper Sandler began coverage on shares of Connect Biopharma in a research note on Friday, June 26th. They set an “overweight” rating and a $7.00 price objective on the stock. Wall Street Zen raised shares of Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Canaccord Genuity Group dropped their price target on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, September 16th. BTIG Research decreased their price objective on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. Finally, Oppenheimer lowered their target price on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, September 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.14.

Connect Biopharma Stock Down 6.8%

Shares of NASDAQ CNTB traded down $0.06 on Thursday, hitting $0.88. The company had a trading volume of 1,210,032 shares, compared to its average volume of 1,441,842. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 12-month low of $0.85 and a 12-month high of $3.82. The firm has a market capitalization of $55.46 million, a P/E ratio of -0.74 and a beta of -0.16. The business has a 50 day moving average of $1.83 and a two-hundred day moving average of $2.23.

Connect Biopharma (NASDAQ:CNTB) last announced its earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. The company had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $0.74 million. As a group, equities research analysts forecast that Connect Biopharma will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Connect Biopharma

Several institutional investors have recently added to or reduced their stakes in CNTB. Bank of America Corp DE acquired a new position in Connect Biopharma in the first quarter worth about $41,000. ADAR1 Capital Management LLC acquired a new stake in Connect Biopharma during the first quarter valued at approximately $1,945,000. Knott David M Jr lifted its holdings in Connect Biopharma by 93.9% during the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after buying an additional 187,835 shares during the last quarter. Simplify Asset Management Inc. bought a new position in Connect Biopharma during the 1st quarter worth approximately $135,000. Finally, Richmond Brothers Inc. acquired a new position in shares of Connect Biopharma in the 4th quarter worth approximately $489,000. 58.72% of the stock is owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.